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I.

Introduction
Chagas disease is a serious parasitic infection that affects at
least 6 million people in the world. 1 An estimated 300,000 Chagas
disease patients live in the United States. 2 Until recently, no FDA
approved treatment for Chagas disease existed. 3 The FDA’s Priority
Review Voucher incentive program was a key factor in the recent
FDA approval of benznidazole for the treatment of Chagas Disease. 4

1

Chagas Disease (American Trypanosomisasis), WORLD HEALTH
ORG. (last updated Mar. 2017),
http://www.who.int/mediacentre/factsheets/fs340/en/ [hereinafter
WHO] (fact sheet) (stating that Chagas disease is “also known as
American Trypanosomiasis).
2

Chagas Disease, FOOD & DRUG ADMIN. (last updated Oct. 12,
2017),
https://www.fda.gov/ForConsumers/ByAudience/MinorityHealth/uc
m466121.htm.
3

Thomas Morrow, MD, FDA Gives First-Ever Approval of Drug to
Treat Chagas Disease, (Nov. 2017),
https://www.managedcaremag.com/archives/2017/11/fda-gives-firstever-approval-drug-treat-chagas-disease (“Until recently, there was
no treatment bearing the FDA’s stamp of approval for Chagas’ [sic]
disease.”).
4

See Press Release, FDA, FDA Approves First Treatment for
Chagas Disease (Aug. 29, 2017),
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm573942.htm [hereinafter Press Release FDA Approves]
(explaining that the FDA granted a priority review voucher to the
drug sponsor of benznidazole and that “[t]he FDA is committed to
making available safe and effective therapeutic options to treat
tropical diseases”).
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This article describes the role of the FDA Priority Review
Voucher program in the recent FDA approval of benznidazole for
Chagas disease. This article’s first section details the background
and current status of the FDA Priority Review Voucher program. 5
The next section explains the sale of priority review vouchers. 6 This
article then explores the impact, benefits, and limitations of the
Priority Review Voucher Program. 7 Part II ends with a brief
description of the FDA’s Orphan Drug status designation. 8
Part III begins by describing Chagas disease and its
discovery.9 This part then addresses the history of Chagas disease
treatments.10 This article then explains the events surrounding the
recent FDA approval of benznidazole for the treatment of Chagas
disease.11 This article concludes by assessing the FDA Priority
Review Voucher program’s role in the benznidazole approval and
addresses legislative concerns going forward. 12
II.
History and Background Section
A. Relationship Between Patent Law and Pharmaceutical Companies
Many diseases in developing countries are untreated because
patent law monopolies price the necessary medications out of the
financial reach of poor countries’ inhabitants.13 Although many

5

See infra Parts IIA., B., C.

6

See infra Part IID.

7

See infra Parts IIE., F.

8

See infra Part IIG.

9

See infra Parts IIIA., B.

10

See infra Part IIIC.

11

See infra Part IV.

12

See infra Part V.

13

Robert C. Bird, Developing Nations and the Compulsory License:
Maximizing Access to Essential Medicine While Minimizing
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factors contribute to the lack of available medications in developing
countries, the tight relationship between U.S. governmental patent
law and multinational pharmaceutical corporations provides the
cornerstone to “this global health crisis.” 14 Multinational
pharmaceutical corporations utilize government-approved
monopolies to control medications’ use and sale. 15 Patents to
medications allow pharmaceutical corporations to raise prices into
the unaffordable range for patients who need the medications the
most.16 Multinational corporations claim that high research and
development costs impede their ability to lower medication prices. 17
Additionally, multinationals cite the potential for trafficking of

Investment Side Effects, 37 J.L. MED. & ETHICS 209, 209 (2009)
(“Many of the health problems facing the developing world do not
arise from a lack of understanding of complex diseases. Rather, the
problem arises from a striking lack of availability of life saving
medications for the consumers that need these medicines the most.”).
14 Id. (stating that “the publicity spotlight . . . has shined largely on
the alliance of strong, government-legislated patent law and the
multinational corporation” as a cause of poor medication access in
developing countries).
15 Id.; Marcia Angell, The Truth About Drug Companies, THE N.Y.
REV. OF BOOKS (July 15, 2004),
https://alojamientos.uva.es/guia_docente/uploads/2013/478/46299/1/
Documento2.pdf (stating that the pharmaceutical industry is “utterly
dependent on government-granted monopolies—in the form of
patents and Food and Drug Administration (FDA)-approved
exclusive marketing rights”).
16
Bird, supra note 13 at 209 (stating that “[m]ultinationals owning
patents to medicines raise prices” such that the needed treatments
“become unaffordable to the poorest consumers who need them”).
17

Bird, supra note 13 at 209; Angell, supra note 15 at 1 (quoting a
pharmaceutical company spokeswoman as explaining that “’[p]rice
increases are not uncommon in the industry and that allows us to
invest in R&D’” (research and development)).

CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW

236

medications from developing countries to wealthier nations. 18
However, critics believe that multinationals sacrifice impoverished
countries’ citizens’ health to increase profit margins. 19

18
19

Bird, supra note 13 at 209.

Bird, supra note 13 at 209; Angell, supra note 15 at 3 (stating that
research and development costs comprise a minor portion of
(pharmaceutical corporations’ spending and that “the prices drug
companies charge have little relationship to cost of making drugs
and could be cut dramatically without coming anywhere close to
threatening [research and development]”).
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B. United States Food and Drug Administration Priority
Review
In 2006, a trio of Duke University faculty members published
a paper suggesting the use of priority review vouchers to incentivize
drug companies to manufacture “essential drugs in developing
countries.”20 The paper proposed that the FDA grant transferrable
vouchers that would significantly decrease FDA approval times for
drugs treating neglected tropical diseases (“NTDs”). 21 The voucher
idea “caught the attention” of members of Congress, and in 2007,
President Bush signed the Food and Drug Administration Amendment
Act (FDAAA) that included provisions for priority review vouchers
(“PRVs”).22 The Act states that the FDA may issue a PRV to a
pharmaceutical company that receives approval for a new drug
application (“NDA”) or a biologics license application (“BLA”) for a
new chemical entity (“NCE”) to treat an NTD. 23 The pharmaceutical
company may then apply the PRV toward a different medicine that
the company wishes to market. 24 Conversely, a pharmaceutical
company may sell its PRV to another drug manufacturer. 25 As of
2016, the average sale price for a PRV was $200 million. 26 Thus, the
PRV acts as a “prize” to encourage pharmaceutical companies to
complete the required steps for FDA approval. 27 In 2012, President
Barack Obama signed the Food and Drug Administration Safety and
Innovation Act (FDASIA), which provided the FDA with authority
to grant PRV for treatments of rare pediatric diseases.28

20

David B. Ridley et al., Developing Drugs for Developing
Countries, 25 HEALTH AFFAIRS 313, 313 (2006),
https://www.healthaffairs.org/doi/pdf/10.1377/hlthaff.25.2.313
[hereinafter Ridley, Developing Drugs] (listing Chagas disease as an
example of a “neglected disease”).
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Id. at 322 (explaining that “[i]n a well-functioning voucher
market,” priority review vouchers would “speed access to highly
valued treatments,” allowing drugs for treating diseases in
developing countries to reach patients more quickly); David Ridley,
Priority Review Vouchers, PRIORITY REV. VOUCHERS (last visited
Dec. 16, 2017), http://priorityreviewvoucher.org [hereinafter Ridley,
Priority Review Vouchers] (listing the NTDs eligible to PRVs
including blinding trachoma, cholera, dengue, leprosy, malaria,
tuberculosis, as well as Chagas disease, which the FDA added in
2015); Why are some tropical diseases called “neglected”?, WORLD
HEALTH ORG. (Jan. 2012), http://www.who.int/features/qa/58/en/
(“Neglected tropical diseases persist in under conditions of poverty
and are concentrated almost exclusively in impoverished populations
in the developing world.”).
21

22

Jonathan Berman, The Tropical Disease Priority Review Voucher:
A Game-Changer for Tropical Disease Products, 96 AM. J.
TROPICAL MED. HYGIENE 11, 12 (2017),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239674/;
Alexander Gaffney, Regulatory Explainer: Everything You Need to
Know About FDA’s Priority Review Vouchers, REG. AFF. PROFS.
SOC’Y (Nov. 29, 2017), http://www.raps.org/RegulatoryFocus/News/2015/07/02/21722/Regulatory-Explainer-EverythingYou-Need-to-Know-About-FDA’s-Priority-Review-Vouchers/;
Ridley, Priority Review Vouchers, supra note 21; see Food and Drug
Administration Amendment Act of 2007, Pub. L. No. 110-85, 121
Stat. 823, https://www.gpo.gov/fdsys/pkg/STATUTE121/pdf/STATUTE-121-Pg823.pdf.
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21 C.F.R. § 314.108 (2016) (“New chemical entity means a drug
that contains no active moiety that has been approved by the FDA in
any other NDA submitted under section 505(b) of the Federal Food,
Drug, and Cosmetic Act.”); Berman, supra note 22 at 12; Biologics
License Applications (BLA) Process (CBER), U.S. FOOD & DRUG
ADMIN. (last updated Nov. 5, 2015),
https://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprova
lProcess/BiologicsLicenseApplicationsBLAProcess/default.htm
(“The Biologics License Application (BLA) is a request for
permission to introduce . . . a biologic product into interstate
commerce (21 CFR 602.1).”); New Drug Application (NDA), U.S.
FOOD & DRUG ADMIN. (last updated March 29, 2016),
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrug
sareDevelopedandApproved/ApprovalApplications/NewDrugApplic
ationNDA/default.htm (“The NDA application is a vehicle through
which drug sponsors formally propose that the FDA approve a new
pharmaceutical for sale and marketing in the U.S.”).
23

24

Berman, supra note 22 at 12.

Id. (“The PRV is transferrable and can be sold for use with any
other product.”).
25

26

David B. Ridley, Priorities for the Priority Review Voucher, 96
AM. J. TROPICAL MED. HYGIENE 14, 15 (2017),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239680/
[hereinafter Ridley, Priorities] (explaining that as of June 2016, 4
out of the 10 PRV recipients had sold their vouchers); see also
Gaffney, supra note 22 (stating that as of June 2017, PRV sale prices
have ranged from $ 67 million to $350 million).
27

Ridley, Developing Drugs, supra note 20 at 316–18 (explaining
“push” and “pull” mechanisms for stimulating drug development and
describing the PRV strategy a “pull mechanism”); Ridley, Priority
Review Vouchers, supra note 24 (referring to a PRV as a “prize” in
the context of discussing the limitations of the PRV program).
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21 U.S.C. §§ 360bb, 360ff (2012),
https://www.gpo.gov/fdsys/pkg/USCODE-2012title21/pdf/USCODE-2012-title21-chap9-subchapV-partBsec360bb.pdf; https://www.gpo.gov/fdsys/pkg/USCODE-2012title21/pdf/USCODE-2012-title21-chap9-subchapV-partBsec360ff.pdf (defining a “rare pediatric disease” as one that
“primarily affects individuals aged birth to 18 years” and “which (A)
affects less than 200,000 persons in the United States, or (B) affects
more than 200,000 persons in the United States and for which there
is no reasonable expectation that the cost of developing and making
available in the United States a drug for such disease or condition
will be recovered from sales in the United States of such drug”);
FDA: Recently Signed PDUFA 5 Provisions to Address Drug
Shortages, POL’Y & MED. (July 18, 2012),
http://www.policymed.com/2012/07/fda-recently-signed-pdufa-5provisions-to-address-drug-shortages.html; Rare Pediatric Disease
Priority Review Voucher Program, U.S. FOOD & DRUG ADMIN. (last
updated Nov. 2, 2017),
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseas
esConditions/RarePediatricDiseasePriorityVoucherProgram/default.
htm.
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C. FDA’s Priority Review Vouchers
All prescription medications marketed in the United States
must receive FDA approval. 29 To receive approval, each drug must
undergo the FDA’s review process. 30 The review process is a “twotiered” system that includes standard review and priority review. 31
Drugs with a standard review designation normally receive an FDA
decision concerning approval 10 months after a manufacturer submits
an NDA.32 In contrast, the decision time for drugs with a priority
review designation is 6 months.33 The FDA grants a standard review
or a priority review designation for all NDAs and BLAs. 34
Additionally, a drug manufacturer may request a priority review
designation.35 PRVs provide yet another mechanism by which a drug
may receive priority review designation. 36

29

What is the Approval Process for a New Prescription Drug?, U.S.
FOOD & DRUG ADMIN. (last updated Nov. 11, 2017)
https://www.fda.gov/AboutFDA/Transparency/Basics/ucm194949.ht
m.
30

Priority Review Vouchers, U.S. FOOD & DRUG ADMIN. (last
updated Sept. 9, 2014),
https://www.fda.gov/ForPatients/Approvals/Fast/ucm405405.htm
[hereinafter FDA Priority Review].
31

Id.

32

Id.; Step 4: FDA Review, U.S. FOOD & DRUG ADMIN. (last updated
Apr. 26, 2017),
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405570.htm.
33

FDA Priority Review, supra note 30.

34

Id.

35

Id.
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Gaffney, supra note 22 (detailing the differences between “What
the Priority Review Designation Process Normally Looks Like” and
“How the Priority Review Voucher System Works” in a chart).
36
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The FDA provides priority review designations to drugs that
“would be significant improvements in the safety or effectiveness of
the treatment, diagnosis, or prevention of serious conditions when
compared to standard applications.” 37 A priority review designation
does not decrease the clinical trial period’s length, nor does it “alter
the scientific standard for approval or the quality of evidence
necessary.”38 Instead, the priority review designation “is intended to
direct overall attention and resources to the evaluation of such
applications.”39 The FDA also grants priority review designation to
treatments for pediatric patients and for infectious diseases. 40Priority
review is one of four FDA approaches that strive to increase the speed
with which drugs become available in the United States. 41

FDA Priority Review, supra note 30 (listing “elimination or
substantial reduction of a treatment-limiting drug reaction;
documented enhancement of patient compliance,” and “evidence of
safety and effectiveness in a new subpopulation” as examples of
“significant improvement”);
37

38

Id.

39

U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: EXPEDITED
PROGRAMS FOR SERIOUS CONDITIONS—DRUGS AND BIOLOGICS 24
(2014),
https://www.fda.gov/downloads/drugs/guidancecomplianceregulator
yinformation/guidances/ucm358301.pdf [hereinafter GUIDANCE].
Id. (describing a “supplement that proposes a labelling change
pursuant to report on a pediatric study” and an “application for a
drug that has been designated
as a qualified infectious disease
product”).
40
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Fast Track, Breakthrough Therapy, Accelerated Approval,
Priority Review, U.S. FOOD & DRUG ADMIN. (last updated Sept. 4,
2015), https://www.fda.gov/ForPatients/Approvals/Fast/default
(noting that although “each of [the four] approaches implies speed,”
they constitute “four distinct and successful approaches to making
such drugs as rapidly as possible”).
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D. Sale of PRVs
Another beneficial characteristic of PRVs is their
transferability.42 Instead of utilizing the PRV to obtain priority review
for one of its own products, a PRV holder may sell the PRV to another
drug manufacturer. 43 To illustrate the potential economic value of a
PRV, consider a small pharmaceutical company with a PRV for an
NTD.44 The PRV’s value may be essentially equivalent to the
company’s value. 45 Not surprisingly, new business models have come
into existence with the goal of utilizing the PRV program as a valuable
financial tool. 46

42

Ridley, Priority Review Vouchers, supra note 21.

43

Gaffeny, supra note 22 (explaining that a PRV holder can either
redeem the voucher for its own use or sell the voucher to “another
company, which might to have its own drug reviewed in a six-month
timeline”).
44

See David B. Ridley, Fuqua Research into Action: The Priority
Review Voucher, https://faculty.fuqua.duke.edu/~dbr1/voucher/
[hereinafter Ridley, Fuqua Research] (video) (giving an example of
a company who held a voucher from the manufacturing of a drug for
leishmaniasis).
45

Id. (describing bankers seeking information concerning the value
of a PRV to determine the value of a company).
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E. Impact and Benefits of PRVs
A PRV provides a drug manufacturer with a priority review
designation for use with a future drug.47 The manufacturer does not
use the PRV for the NTD medication; instead, the manufacturer uses
the PRV for a different drug. 48 Although the PRV-qualifying NTD
drug does not utilize a PRV, the NTD drug must also qualify for
priority review “on its own merit.” 49A PRV allows a new drug to
arrive on the U.S. market sooner than its competitors, thus increasing
the potential for a pharmaceutical company to release a blockbuster
drug.50

46

Chris Bialas, Analyzing the FDA Priority Review Voucher
Programs Stimulation of Research and Public Health Impact, 3
TECHNOLOGY TRANSFER & ENTREPRENEURSHIP 131, 137 (2016),
https://www.researchgate.net/profile/Dennis_Gross/publication/3058
23499_Analyzing_the_FDA_Priority_Review_Voucher_Program%2
7s_Stimulation_of_Research_and_Public_Health_Impact/links/5874
ef4308ae6eb871c97e36/Analyzing-the-FDA-Priority-ReviewVoucher-Programs-Stimulation-of-Research-and-Public-HealthImpact.pdf (“This interest has even spawned new business models
based on the development of target designation treatments in order to
acquire and sell PRVs.”)
47

Gaffeny, supra note 22; Ridley, Priority Review Vouchers, supra
note 21.
Ridley, Priorities, supra note 26 (“Thus, two drugs are involved:
the drug that wins a bonus priority review and the drug that uses the
bonus priority review.”).
48

49

Ridley, Priorities, supra note 26 at 15.

50

Id.; David B. Ridley, Fuqua Research, supra note 44.
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Three value sources for PRV holders exist. 51 First, a PRV
allows a manufacturer to release its product into the market sooner
than standard review would allow. 52 Second, a PRV provides a longer
on-market experience for the pharmaceutical company’s product. 53
Third, a PRV provides a drug manufacturer with “competitive
benefits” that may allow the voucher holder to “launch” their product
closer to or even before a competitor’s product. 54

51

Ridley, Fuqua Research, supra note 44.

Id. (noting that reaching the market earlier increases the “time
value of money”).
52

Id. (explaining that “you launch earlier and have the same
effective patent expiration date, in many cases”).
53

54

Id.
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The PRV program provides two important benefits to
healthcare.55 First, PRVs encourage drug companies to complete the
necessary research and development for rare and neglected disease
treatments.56 Without the attraction of a PRV, few drug companies
would invest in medicines to treat NTDs.57 Accordingly, before the
PRV program, few pharmaceutical companies applied for patents on
their “essential medicines” distributed to low-to mid-income
countries.58

55

Ridley, Priority Review Vouchers, supra note 21.

56

GUIDANCE, supra note 39 (requiring clinical trials, clinical testing,
“randomized trials, other types of controls . . . for example, historical
controls” as “an attempt to show superiority relating to either safety
or effectiveness”); Ridley, Priority Review Vouchers, supra note 21.
Gaffeny, supra note 22 (“FDA’s priority review vouchers . . . are
incentives meant to spur the development of new treatments for
diseases that would otherwise not attract development interest from
companies due to the cost of development and the lack of market
opportunities.”).
57

58

Amir Attaran, How Do Patents and Economic Policies Affect
Access to Essential Medicines in Developing Countries? 23 HEALTH
AFFAIRS 155, 155, 159 (2004),
https://www.healthaffairs.org/doi/pdf/10.1377/hlthaff.23.3.155
(finding that pharmaceutical companies usually did not seek patents
in developing countries, even when they legally had the option).
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Second, PRV program allows “potential blockbuster” drugs to
reach U.S. patients more quickly. 59 Data suggests that priority review
status increases a drug’s likelihood of obtaining blockbuster status. 60
While some drugs achieve blockbuster status without priority review
designation, pharmaceutical companies and patients lose the benefits
of expedited FDA approval. 61 Because the FDA “direct[s] overall
attention and resources” to drugs with priority review status, the
voucher holder must pay a fee to redeem the PRV. 62 This user fee
allows the FDA to obtain the necessary resources to expedite the
review of the PRV drug without delaying the review of other
medications.63Thus, the PRV program provides sources of
medications to treat NTD without incurring U.S. taxpayer costs or
delayed FDA review of other medications. 64 The PRV program
inspired the United States Patent and Trademark Office to create an
awards competition to recognize “innovators who use game-changing
technology to meet global humanitarian challenges.” 65

59

Ridley, Priority Review Vouchers, supra note 21; What Is a
Blockbuster Drug?, THE MOTLEY FOOL (last visited Dec. 18, 2017),
https://www.fool.com/knowledge-center/what-is-a-blockbusterdrug.aspx (“Blockbuster drugs are those that generate at least $1
billion is revenue a year for the pharmaceutical companies that
produce them.”).
60

Ridley, Developing Drugs, supra note 20 (noting that during the
1990s, “fourteen of the twenty-nine ‘blockbuster drugs’ . . . were
classified as priority”).
61

Id. (listing Zocor, Norvasc, Cozaar, and Zyprexa and examples of
drugs that “[h]ad priority review vouchers been available, these
drugs could have helped patients sooner and earned higher returns”).
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62

Notice, Fee for Using a Tropical Disease Priority Review Voucher
in Fiscal Year 2017, 81 Fed. Reg. 67356
https://www.federalregister.gov/documents/2016/09/30/201623623/fee-for-using-a-tropical-disease-priority-review-voucher-infiscal-year-2017 (stating that the fee category for an “[a]pplication
submitted with a tropical disease priority review voucher in addition
to the normal PDUFA fee” was $2,706,000 for the fiscal year 2017);
Tropical Disease Priority Review Voucher Program, U.S. FOOD &
DRUG ADMIN. (last updated May 24, 2017),
https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalPro
ductsandTobacco/CDER/ucm534162.htm (noting in a table that fees
for tropical disease PRV have ranged from $2,325,000 to $5,280,000
from 2011 to 2018 and that the Tropical Disease PRV User Fee for
the 2018 fiscal year will be $2,830,000; Ridley, Priority Review
Vouchers, supra note 21 (“By moving one drug to faster review,
there is the potential to slow other drugs.”).
63

Ridley, Priority Review Vouchers, supra note 21.

64

Berman, supra note 22 at 13.

65

Request for Comments on Incentivizing Humanitarian
Technologies and Licensing Through the Intellectual Property
System, 75 Fed. Reg. 57261 (Sept. 20, 2010)
https://www.federalregister.gov/documents/2010/09/20/201023395/request-for-comments-on-incentivizing-humanitariantechnologies-and-licensing-through-the; Patents for Humanity,
UNITED STATES PAT. & TRADEMARK OFF. (last updated Nov. 17,
2017), https://www.uspto.gov/patent/initiatives/patentshumanity/learn-more; Ridley, Priority Review Vouchers, supra note
21.
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F. Limitation, risks, and criticisms of the PRV Program
The PRV program contains inherent risk and limitations. 66
Most importantly, the FDA is not required to approve a PRV holder’s
product.67 The FDAAA and FDASIA state that the FDA will come to
a decision on a PRV holders NDA—not that the FDA is obligated to
approve the drug.68 Additionally, although the FDA pledges to
allocate resources to expedite the review of a priority review drug, the
FDA does not guarantee completion of review in the six-month time
frame.69

66

Gaffeny, supra note 22.

67

Id.

68

U.S. FOOD & DRUG ADMIN., TROPICAL DISEASE PRIORITY REVIEW
VOUCHERS: GUIDANCE FOR INDUSTRY 6 (2016),
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulat
oryInformation/Guidances/UCM080599.pdf [hereinafter TDPRV
GUIDANCE] (“Note that an FDA review within a specific time frame
does not mean an application will be approved within that time
frame. The term review and act on is understood to mean the
issuance of an approval or complete response letter after the review
of a filed application.”); Id. (noting that an action letter may not
contain approval); Gaffeny, supra note 22(“As Novartis proved in
the first-ever use of a priority review voucher, FDA will not
necessarily approve a product just because its sponsor used a
voucher. Priority review . . . will not save a bad drug from being
rejected.”).
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GUIDANCE, supra note 39 at 25 (“A priority review designation
means the FDA’s goal is to take action on the marketing application
within 6 months of receipt (compared with 10 months under standard
review).”); TDPRV GUIDANCE, supra note 68 at 5 (stating that the
FDA has “committed to a goal to review and act on 90 percent pf
priority new molecular entity (NME) NDA and original BLA
submissions within 6 month of the 60-day filing date, and 90 percent
of priority non-NME original NDA submissions within 6 months of
receipt”); Gaffeny, supra note 22 (describing the FDA’s lack of
obligation to meet a fixed deadline for approval as a “little-known
limitation”).
69
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Critics of the PRV program highlight several weaknesses of
PRVs.70 First, the drug applying for a PRV must itself earn a priority
review designation. 71 Second, the costs for completing clinical trials
are often higher for NTDs than for rare pediatric diseases, thus making
PRVs less valuable to drug manufacturers developing NTD treatments
than those developing rare pediatric disease treatments. 72 Third,
Congress could decide not to renew the voucher program, thus
exposing drug companies to investment risk. 73 Additionally, variables
such as timing, supply, and competition make predicting a PRV’s sale
value challenging. 74 Fourth, drug manufacturers may receive PRV for
drugs that are currently available outside the United States, thus
defeating the program’s goal of developing novel treatments. 75
Finally, the PRV program does not ensure that the drugs for treating
NTDs will be available or affordable. 76

70

See Berman, supra note 22 at 13; Ridley, Priorities, supra note 26
at 15.
71

TDPRV GUIDANCE, supra note 68 at 2 (stating that a drug
application sponsor is eligible for a tropical disease PRV if “[t]he
application might otherwise be eligible for a priority review”);
Berman, supra note 22 at 11 (stating that the requirement the NDA
product must itself have priority review has “at least three important
ramifications”); Ridley, Priorities, supra note 26 at 14.
Berman, supra note 22 at 12 (“Unlike rare pediatric diseases . . .
tropical diseases . . . require large-scale trials”); Ridley, Priorities,
supra note 26 at 14.
72

Berman, supra note 22 at 12 (“There is legislative risk around the
programs very existence or the rules around its application.”).
73

Id. (explaining that “the timing of a voucher sale is more art than
science”).
74
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75

Helen Branswell, How a System Meant to Develop Drugs for Rare
Diseases Broke Down, STAT (Nov. 28, 2015),
https://www.statnews.com/2015/11/28/priority-review-vouchersrare-diseases/ (explaining the first PRV recipient was a drug
manufacturer of a malaria treatment that “had been licensed outside
the U.S. since 2001 and was already widely in use”); see also David
Ridley, How to Put an Ebola Treatment on Drugmakers’ Radar,
SFGATE (Oct. 12, 2014),
http://www.sfgate.com/opinion/openforum/article/Congress-shouldoffer-vouchers-to-develop-ebola-5818174.php (stating that
“Congress should restrict eligibility for the voucher to novel
products that have not been approved in other countries more than
two years prior to FDA submission”).
76

Ridley, Priorities, supra note 26 at 14; Branswell, supra note 75
(“Drug makers that earn priority review vouchers don’t have to
guarantee that the drugs will actually be available, or sold at an
affordable price.”).
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G. The Orphan Drug Development Program
In 1984, President Ronald Reagan signed the Orphan Drug
77
Act. The Act provided incentives for pharmaceutical companies to
market treatments for rare diseases. 78 These incentives include tax
credits, market exclusivity, and fast-track designation. 79 A drug may
obtain orphan status in two ways. 80 First, the FDA may grant a drug
may orphan status if the drug provides a treatment for a rare
disease.81 Second, the FDA may grant orphan status to a drug for
which “there is no reasonable expectation that the sales of the drug
will be sufficient to offset the costs of developing the drug.”82 While
critics of the Orphan Drug Act have voiced concerns about drug
manufacturers’ abuse of orphan drug status, the Act has contributed
to FDA approval of important blockbuster drugs. 83 Under the FDA’s
Accelerated Approval Pathway, 84 the FDA may grant priority review
designation and orphan drug status to the same medication. 85

77

FDA Marks Orphan Drug Law Milestone, U.S. FOOD & DRUG
ADMIN. (last updated Oct. 24, 2017),
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseas
esConditions/OOPDNewsArchive/ucm333527.htm.
DEP’T OF HEALTH & HUMAN SERVS., THE ORPHAN DRUG ACT:
IMPLEMENTATION AND IMPACT 1 (2001),
https://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf.
78
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Id. at 4 (listing the Act’s incentives as “(1) 7-year market
exclusivity . . . (2) a tax credit of 50 percent of the cost of conducting
human clinical trials, and (3) Federal research grants for clinical
testing”); id. (“In 1997, Congress created an additional incentive
when it granted companies developing orphan products an
exemption from the usual drug application or “user” fees charged by
the Food and Drug Administration (FDA).”); Orphan Drugs in the
United States, ORPHANET (last updated Dec. 19, 2017),
http://www.orpha.net/consor/cgibin/Education_AboutOrphanDrugs.php?lng=EN&stapage=ST_EDU
CATION_EDUCATION_ABOUTORPHANDRUGS_USA
(describing additional orphan drug sponsor incentives as “some
written recommendations provided by the FDA concerning clinical
and preclinical studies to be completed in order to register the new
drug” and “a fast-track procedure for the FDA to evaluate
registration files”).
79

80

Aarti Sharma, Orphan Drug: Development Trends and Strategies,
2 J. PHARMACY & BIOALLIED SCI. 290, 290 (2010),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996062/;
Designating an Orphan Product; Drugs and Biological Products,
U.S. FOOD & DRUG ADMIN. (last updated Dec. 19, 2017),
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseas
esConditions/HowtoapplyforOrphanProductDesignation/default.htm;
Developing Products for Rare Diseases & Conditions, U.S. FOOD &
DRUG ADMIN. (last updated Dec. 19, 2017),
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseas
esConditions/ucm2005525.htm.
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81

21 C.F.R. § 316.21(a)(1) (2013), https://www.ecfr.gov/cgibin/retrieveECFR?gp=&SID=718f6fcbc20f2755bd1f5a980eb5eecd
&mc=true&n=sp21.5.316.c&r=SUBPART&ty=HTML#se21.5.316_
120 (defining the a rare disease as one “that the number of people
affected by the disease or condition for which the drug is developed
is less than 200,000”); Sharma, supra note 80 at 290 (“A medicinal
product designated as an orphan drug is one that has been
specifically developed to treat a rare medical condition, the condition
itself being referred to as an ‘orphan disease’”).
82

21 C.F.R. § 316(a)(2) (describing the parameters for orphan status
regarding the drugs development to sales cost ratio in the United
States).
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James Bohan, Orphan Drugs and Why Everybody Wants One!,
IDEA PHARMA (Mar. 15, 2017),
http://ideapharma.com/junkie/orphan-drugs-and-why-everyonewants-one; Sarah Jane Tribble, Drugs for Rare Diseases Have
Become Uncommonly Rich Monopolies, NPR (Jan. 17, 2017),
https://www.npr.org/sections/healthshots/2017/01/17/509506836/drugs-for-rare-diseases-have-becomeuncommonly-rich-monopolies (reporting information demonstrating
that “the system intended to help desperate patients is being
manipulated by drugmakers to maximize profits and to protect niche
markets for medicines already taken by millions”); id. ( listing
Humira, Enbrel, Remicade, and Rituxan as examples of orphan
drugs that became blockbusters); Sarah Jane Tribble, FDA Moves to
Rein in Drugmakers’ Abuse of Orphan Drug Law, NPR (Sept. 13,
2017), https://www.npr.org/sections/healthshots/2017/09/13/550700062/fda-moves-to-rein-in-drugmakersabuse-of-orphan-drug-law (stating that “many drugs that now have
orphan status are not entirely new” and that the FDA “plans to close
a loophole that allows manufacturers to skip pediatric testing
requirements when developing a mass-market drug for treating rare
diseases in children”). But see Walter Armstrong, Pharma’s
Orphans, PHARMEXEC.COM (May 1, 2010),
http://www.pharmexec.com/pharmas-orphans (“The legislation is
almost universally viewed as a roaring success.”)
84

Accelerated Approval, U.S. FOOD & DRUG ADMIN. (last updated
Sept. 15, 2014),
https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm.
85

See Press Release FDA Approves, supra note 4 (stating that the
treatment for Chagas disease received priority review and orphan
status).

CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW

259

III. History of Chagas Disease Treatment
A. Description of Chagas Disease
Chagas disease (American Trypanosomiasis) results from the
infection of the protozoan parasite Trypanosoma cruzi.86 Contact
with the urine or feces of triatomine bugs infects humans. 87 Infected
insects emerge at night from their daytime hiding places in the
cracks of walls and roofs to bite humans.88 When the person rubs or
itches the bite area, parasite-infected feces and salvia enter the
wound.89 Additionally, the Chagas parasite may infect patients via
blood transfusions, contaminated food consumption, laboratory
accidents, organ transplants, and mother-to-unborn child
transmission.90

TINTINALLI’S EMERGENCY MEDICINE, 1102 (Judith Tintinalli, ed.,
2016).
86

(indicating that triatomine bugs are also known as “kissing
bugs” and “assassin bugs”); WHO, supra note 1.
87Id.

88

WHO, supra note 1; TINTINALLI, supra note 86 at 1102.

89

TINTINALLI, supra note 86 at 1102; WHO, supra note 1 (stating
that the “parasites enter the body when the person instinctively
smears the bug feaces [sic] or urine into the bite, the eyes, the mouth,
or any skin break”).
90

TINTINALLI, supra note 86 at 1102; WHO, supra note 1.
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Persons infected with the parasite first experience
inflammation around one eye (Romaña’s sign) or painful swelling at
the bite site.91 Chagas disease sufferers typically experience two
phases of the illness: an acute and a chronic phase. 92 During the
acute phase, which typically lasts two to 4 weeks, infected persons
may experience “fever, headache, enlarged lymph glands, pallor,
muscle pain, difficulty in breathing, swelling, and abdominal or
chest pain.”93
After the acute phase, the untreated disease enters a latent,
chronic stage, in which the infected person experiences few
symptoms.94 During the chronic phase, the parasite remains dormant
in heart, nerve, and muscle cells. 95 The disease gradually destroys
nervous and cardiac tissue, which can lead to heart disease,
gastrointestinal malfunction, and sudden death. 96
91

TINTINALLI, supra note 86 at 1102 (describing the swollen area
around the bite as a “chagoma”).
92

TINTINALLI, supra note 86 at 1102; WHO, supra note 1.

93

TINTINALLI, supra note 9 at 1102 (noting that acute-phase may
“last up to 3 months” and may involve high levels of the parasite in
the blood stream, as well as swelling of the liver and spleen); WHO,
supra note 1.
94

TINTINALLI, supra note 86 at 1102; WHO, supra note 1; see Latent
infection, THE FREE DICTIONARY (2017), https://medicaldictionary.thefreedictionary.com/latent+infection (defining a latent
infection as one that is “asymptomatic” but “capable of manifesting
symptoms under particular circumstances,” and that “does not
produce visible signs of a disease but may be transmitted to another
host”).
95

TINTINALLI, supra note 86 at 1102; WHO, supra note 1.

TINTINALLI, supra note 86 at 1102 (stating that “Chagas-induced
heart disease in the leading form of congestive heart failure in much
of Latin America”); WHO, supra note 1.
96
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Physicians diagnose acute-phase Chagas disease by taking
blood samples or muscle biopsies.97 To diagnose Chagas disease in
the chronic phase, physicians may utilize specialized blood tests or
targeted organ tissue biopsies. 98
Two medications successfully kill the Trypanosoma cruzi
protozoan—benznidazole and nifurtimox. 99 These medications have
an almost one hundred percent cure rate for patients in the acute
phase of Chagas disease.100 However, this exceptional efficacy rate
is only applicable if the infected person receives the medication
“soon after infection at the onset of the acute phase.” 101 The
continued efficacy of the treatment decreases in a manner inversely
proportional to the length of time the person has been infected. 102
Thus, the longer the delay in treatment, the less effective the
medications are against Chagas disease. 103

97

TINTINALLI, supra note 86 at 1102 (noting that the blood or tissue
samples may demonstrate “motile parasites”).
98

Id.

Id. at 1102 (stating that these medications “are available in the
United States through the Centers for Disease Control”); WHO,
supra note 1.
99

100

WHO, supra note 1 (adding that benznidazole and nifurtimox
“are almost 100% effective in curing the disease if given soon after
infection . . . [in] cases of congenital transmission”).
101

Id.

See id. (noting that the treatments’ efficacy also decreases with
increased length of infection time in cases of post-natal maternalfetal transmission).
102

103

Id.
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No vaccine exists to prevent Chagas disease. 104 Thus,
controlling transmission through triatomine bugs, transfusions, and
transplants is the mainstay of Chagas disease prevention. 105 The
World Health Organization’s Chagas disease prevention and control
measures include insecticide use, improved food-preparation
hygiene, structural home improvements, and blood donor
screening.106

104

Id.

Id. (explaining that “[o]riginally . . . T. cruzi only affected wild
animals” and that the “large reservoir of T. cruzi parasites in wild
animals in the Americas means that the parasite cannot be
eradicated”).
105

WHO, supra note 1 (suggesting “spraying of houses and
surrounding areas with residual pesticides,” repairing cracked walls
and roofs in houses, using bednets, “testing of organ, tissue, or cell
donors and receivers,” and “screening of newborns and other
children of infected mothers”).
106
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Chagas disease is epidemic in twenty-one Latin American
countries, affecting between six and seven million persons
worldwide.107 Although Chagas disease has historically been
confined to Latin America, recent decades have seen the Chagas
disease distribution expand to include the parts of the United States,
Canada, Europe, and western Pacific countries. 108

107

Id. at n.1 (listing countries with endemic areas of Chagas Disease
as Argentina, Belize, Bolivia, Brazil, Chile, Columbia, Costa Rica,
Ecuador, El Salvador, French Guiana, Guatemala, Guyana,
Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname,
Uruguay, and Venezuela); Data & Statistics, CTRS. FOR DISEASE
CONTROL & PREVENTION (last updated Oct. 25, 2017) (providing
data for endemic-level diseases in the United States, including Lyme
disease, tuberculosis, and viral hepatitis); Principles of Epidemiology
in Public Health Practice, Third Edition: An Introduction to Applied
Epidemiology and Biostatistics, CTRS. FOR DISEASE CONTROL &
PREVENTION (last updated May 18, 2012),
https://www.cdc.gov/ophss/csels/dsepd/ss1978/lesson1/section11.ht
ml (describing an endemic level of disease as one that is the
“baseline” level that is the “observed level” that is “usually present
in a community,” and that “[i]n the absence of intervention and
assuming that the level is not high enough to deplete the pool of
susceptible persons, the disease may continue to occur at this level
indefinitely”).
TINTINALLI, supra note 86 at 1102 (“The protozoan Trypanosoma
cruzi is found in up to 5% of emigrants from endemic parts of Latin
America”); WHO, supra note 1 (stating that “Chagas disease occurs
principally in the continental part of Latin America and not in the
Caribbean isles” and that the spread of Chagas disease to other parts
of the world “is due mainly to population mobility between Latin
America and the rest of the world”).
108
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B. History of Chagas Disease
In 1908, a scientist named Carlos Justianio Ribiero de Chagas
began dissecting “large blood-sucking insects” as part of an effort to
combat malaria in railway construction camps in Brazil. 109 Chagas
discovered “numerous trypanosomes” in the insects and gave the
pathogen the name Trypanosoma cruzi.110 Chagas allowed infected
insects to bite laboratory animals and learned that “the parasite was
infective to several . . . laboratory animals.” 111 Chagas deduced that
the trypanosomes caused an unidentified human illness.112

Dietmar Steverding, The History of Chagas Disease, U.S. NAT’L
LIBR. MEDICINE 1, 3 (Jul. 10, 2014),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105117/
[hereinafter Steverding, History] (stating that Carlos Chagas (1879–
1934) was “a Brazilian hygienist and bacteriologist” who “was made
aware by a railroad engineer of large blood-sucking insects which
lived en masses in local dwellings and bit sleeping people
preferentially in the face”).
109

Id. at 3 (explaining that Chagas “named T. cruzi in honor of his
mentor, the Brazilian physician and bacteriologist Oswaldo Cruz
(1872–1917)); See An Introduction to Molecular Parasitology and
Trypanosomes, ROCKEFELLER U. (last visited Dec. 20, 2017),
http://tryps.rockefeller.edu/trypsru2_introduction.html (describing
Trypanosomes as “microscopic unicellular protozoa that are
ubiquitous parasites of . . . mammals” and cause diseases such as
Chagas disease).
110

111

Steverding, supra note 109 at 3–4.

Id. at 4 (“Chagas was sure he had found a pathogenic organism of
a human infectious disease but he did not know what kind of
sickness it was.”).
112
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In 1909, Chagas examined a feverish two-year old girl named
Bernice whose spleen, liver, and lymph nodes were enlarged. 113
Although Chagas did not find T. cruzi in Bernice’s blood during his
first examination, four days later, Chagas discovered “numerous
trypanosomes” in her blood. 114 Chagas described the illness’s acute
phase and “linked the infection with some chronic symptoms of the
illness.”115 Although Bernice never developed the chronic phase of
the disease, she was infected with T. cruzi her entire life.116

113

Id.

Id. (stating that the trypanosomes in Bernice’s blood were of
“similar morphology” to those found in the infected laboratory
animals’ blood).
114

Id. (noting that Chagas’s ability to connect the two phases of the
disease “was remarkable considering that the chronic phase of
American trypanosomiasis usually appears decades after the first
inoculation with T. cruzi”); Aluízio Prata, Evolution of the Clinical
and Epidemiological Knowledge of Chagas Disease 90 Years After
its Discovery, 94 MEMORÍAS DO INSTITUTO OSWALDO CRUZ 81, 82
(1999),
https://pdfs.semanticscholar.org/f513/a6c4bc9ea465663cebe3fcee39
5a92aa8631.pdf (stating that in a preliminary note dated July 5,
1910, Chagas “stated that there were three modalities of the disease:
one acute and two chronic”).
115

116

Steverding, History, supra note 109 at 4 (noting that Bernice died
at the age of 73 “on unrelated causes”); See M. de Lana et al.,
Characterization of Two Isolates of Trypanosoma Cruzi Obtained
from the Patient Bernice, the First Human Case of Chagas’ Disease
by Carlos Chagas in 1909,
https://www.ncbi.nlm.nih.gov/pubmed/8801560/ (“Two isolates of
Trypanosoma cruzi were obtained from the patient Bernice . . . when
she was 55 and 71 years old, respectively.”).
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Although Chagas contributed significantly to the identification of
the disease which now bears his name, other scientists played
important roles in the description and understanding of Chagas
disease.117 Chagas’s discovery aroused keen interest in the
international scientific community at the time. 118 Chagas received
many international recognitions, including two Nobel Prize
nominations.119 However, Chagas’s rapid rise to fame brought
“animosity and envy in his own country.” 120 After experiencing
sabotaging actions from his own lab, 121 scientists and colleagues
from Brazil claimed that Chagas disease was only a local
phenomenon and that the parasite was of “little virulence.” 122 Some
of Chagas’s opponents even accused Chagas of falsifying his
findings and of being unpatriotic. 123 Historians speculate that
Chagas’s countrymen’s animosity toward him “may have cost
[Chagas] the Nobel Prize.” 124 Additionally, the anti-Chagas group’s
actions likely resulted in a twenty-year period in which Chagas
disease was all but “forgotten,” causing research and interest in the
disease to grind to a halt. 125

117

Prata, supra note 115 at 84 (mentioning that the Brazilian
scientist and physician Eurico de Azevedo Villela (1883–1962)
“always worked with Chagas”); Steverding, supra note 109 at 4
(listing Oswaldo Cruz, the Czech zoologist and parasitologist
Stanislaus von Prowazek (1875–1915), the Brazilian pathologist
Gaspar de Oliveira Vianna (1885–1914), and the French pathologist
Alexandre Joseph Émile Brumpt (1877–1951) as contributors to
early Chagas disease research). But see Marillia Coutinho et al., The
Noble Enigma: Chagas’ Nominations for the Nobel Prize, 94
MEMORÍAS DO INSTITUTO OSWALDO CRUZ 123, 127 (1999),
http://www.scielo.br/pdf/mioc/v94s1/ultimo.pdf (“Chagas had just
performed the perfect algorithm from vector to disease within a few
months and alone.”).
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118

Steverding, History, supra note 109 at 5; Rachel Lewinson,
Prophet in His Own Country: Carlos Chagas and the Nobel Prize,
46 PERSPECTIVES IN BIOLOGY & MED. 532–40 (2003),
http://repositorio.unicamp.br/bitstream/REPOSIP/102650/1/2-s2.01542598939.pdf (stating that “Chagas’s discovery brought him
immediate, worldwide acclaim” and that “[h]onors were showered
upon him”);
Coutinho, supra note 117 at 123 (stating that “Chagas was twice
nominated for the Nobel Prize–in 1913 and in 1921–, [sic] but never
received the award”); Lewinson, supra note 118.
119

Coutinho, supra note 117 at 128 (describing the “surreptitious
actions of the early anti-Chagas group” that led to “an unpleasant
incident involving Rudolph Kraus, Director of the Institute of
Bacteriology at Buenos Aires and Chagas’s own laboratory at
Manuinhos”); Lewinson, supra note 118 (noting that “the
overwhelming success of the young scientist from the backwoods of
Minas Gerais set off a reaction of a different kind in some of his
colleagues at Manguinhos, the Faculty and National Society of
Medicine” and that “antagonism against [Chagas] . . . began to flare
up”); Steverding, History, supra note 109 at 5.
120

Coutinho, supra note 117at 128 (“It was clear that someone from
Manguinhos had been feeding . . . contentions against Chagas.”);
Lewinson, supra note 118 (describing Chagas’s reaction at finding
slides from his own laboratory at the Institute of Bacteriology).
121

122

Coutinho, supra note 117 at 128; Lewinson, supra note 118 at
544 (listing some of Chagas’s opponent’s “preposterous
accusations” including that the disease “was restricted to a small area
in Minas Gerias where [Chagas] had found his first cases” and that
“the number of cases did not exceed some 40 patients”).
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123

Coutinho, supra note 117 at 128 (quoting the Brazilian physician
and university president Júlio Afrânio Peixoto as saying: “You could
have found some mosquitos, you could have invented a rare and
unknown disease . . . a disease that you could magnanimously
distribute among your countrymen . . . .”); Lewinson, supra note 118
at 542 (noting that “a grotesque accusation was in store for Chagas:
because he openly discussed the disease and its implications . . . he
was reproached with being unpatriotic; this stupid, pointless charge
was to haunt him for many years.”).
Coutinho, supra note 117 at 128–29 (suggesting that “it was this
local opposition that actually prevented Chagas from being awarded
the Nobel Prize in 1921”); Steverding, History, supra note 109 at 5.
124

Lewinson, supra note 118 at 547–48 (quoting Chagas’s son,
Carlos Chagas Filho, as saying that “[t]o this day, we do not know
how many of our faculties of medicine [at the National Academy of
Medicine in Brazil] never taught Chagas disease”); Carlos M. Morel,
Chagas Disease, from Discovery to Control–and Beyond: History,
Myths, and Lessons to Take Home, 94 MEMORÍAS DO INSTITUTO
OSWALDO CRUZ 3, 4 (1999),
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.326.2200
&rep=rep1&type=pdf (stating that the “strong opposition against
Chagas “had a devastating effect”); Steverding, supra note 109 at 5.
125

CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW

269

In the 1930s, Argentine physician and epidemiologist Salvador
Mazza described thousands of cases of Chagas disease in
Argentina.126 In 1935, Cecilio Romaña described the periorbital
swelling that is commonly present in Chagas disease patients during
the acute phase of the illness.127 Because Romaña’s sign was so
distinctive, the number of reported cases of Chagas disease increased
dramatically after 1935. 128 By 1940, thousands of cases of Chagas
disease had been diagnosed. 129
Morel, supra note 125 at 4 (stating that “[t]he ‘resurrection’ of
Chagas disease is mainly due to the work of Salvador Mazza in
Argentina” and noting that Mazza was “the first one to raise the
possibility of transfusion-transmitted Chagas disease”); Prata, supra
note 115 at 85 (stating that “under the guidance of Mazza, the
reports . . . started to appear, with many acute cases also detected,
especially in Chile and Uruguay”); Steverding, History, supra note
109 at 5.
126

127

What is Chagas disease?, CTRS. FOR DISEASE CONTROL &
PREVENTION (last updated Dec. 19, 2017),
https://www.cdc.gov/parasites/chagas/gen_info/detailed.html
(describing Romaña’s sign as “the most recognized marker of acute
Chagas disease”).
128

Prata, supra note 115 at 85 (noting that Ezequiel Dias and
Evandro Chagas (Carlos Chagas’s son) considered the “discovery of
the Romaña sign” to be “the most valuable foreign contribution to
the disease” and that “thanks to the Romaña sign [sic] which permits
suspecting the disease at a distance, more than 500 cases were
detected in Argentina and about 100 in Uruguay” between 1934 and
1938)
François Delaporte, Romana’s Sign, 30 J. HISTORY BIOLOGY 357,
357 (1997),
https://link.springer.com/article/10.1023/A%3A1004221722554
(“Once thought to be a provincial affliction limited to the state of
Minas Geres, Chagas disease was now seen to be an endemic malady
throughout Latin America.”).
129

CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW

270

C. Development of Chagas Disease Treatments
In the years following his description of Chagas disease,
researchers attempted to find a treatment for Chagas disease. 130
These efforts were unsuccessful, leading Chagas and his son
Evandro to state in 1935 that “there was no specific treatment” for
Chagas disease. 131 Between 1912 and 1962, researchers
experimented with a variety of chemical agents in their endeavors to
find a treatment for Chagas disease. 132 Beginning in 1918,
researchers employed various methods to obtain vector control of the
Chagas disease-transmitting insect. 133

130

José Rodrigues Coura & Solange L. de Castro, A Critical Review
on Chagas Disease Chemotherapy, 97 MEMORÍAS DO INSTITUTO
OSWALDO CRUZ 3, 4 (2002),
http://www.scielo.br/pdf/mioc/v97n1/review.pdf (stating that in
1912 and 1914, Mayer and Rocha Lima experimented with several
agents, including arsenical, rosanilin dye, antimony potassium, and
mercury chloride); Steverding, History, supra note 109 at 5.
131

Coura & Castro, supra note 130 at 4 (stating that Carlos and
Evandro Chagas reported that “[d]rugs with trypanocidal activity
have been assayed by a great number of researchers, but without
success”); Steverding, History, supra note 109 at 5.
132

Coura & Castro, supra note 130 at 4 (listing some of the
“chemotherapeutic agents employed until 1962,” including quinolein
derivatives, bismuth, gentian violet, nicotinic acid hydrazide,
cortisone, and “more than 30 antibiotics and some nitrofurans”).
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WORLD HEALTH ORG., H ANDBOOK FOR INTEGRATED VECTOR
MANAGEMENT 1 n.1 (2012),
http://apps.who.int/iris/bitstream/10665/44768/1/9789241502801_en
g.pdf (“ ‘Vector-borne disease’ is the collective term for infectious
diseases transmitted by insects, snails, or rodents, which act as
vectors of the actual pathogens.”); João Carlos Pintos Dias, The
Beginning of Chagas Disease Control (Homage to Dr. Emmanuel
Dias, the pioneer of Chagas Disease Control, in the Year of His
Birth Centenary), 44 REVISTA DA SOCIEDADE BRASILEIRA DE
MEDICINA TROPICAL 12, 12 (2011),
http://www.scielo.br/pdf/rsbmt/v44s2/a03v44s2.pdf (listing housing
improvements, DDT, fire throwers, and cyanidric gas as agents used
in early attempts at Chagas disease vector control).
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1. Nifurtimox
The first drugs to demonstrate efficacy against Chagas
disease were those belonging to the nitrofuran class. 134 The Eaton
laboratory marketed a type of nitrofuran called nitrofurazone in
Brazil.135 In the 1967, the Bayer pharmaceutical company introduced
the empirically-discovered drug nifurtimox to treat Chagas disease
under the trade name Lampit. 136 In 1997, Bayer ceased production of
nifurtimox due to “lack of profitability.” 137However, in 2000, Bayer
recommenced nifurtimox production as part of the treatment of
African sleeping sickness. 138 In 2004, Bayer agreed to provide the
World Health Organization 500,000 tablets a year at no cost. 139 In
2011, Bayer increased this amount to one million tablets a year,
making this “donated drug . . . the primary source of nifurtimox
worldwide.”140 Nifurtimox is not FDA approved for distribution in
the United States, but the Centers for Disease Control (CDC)
dispenses the drug under its Expanded Access program. 141

134

José Rodrigrues Coura, Present Situation and New Strategies for
Chagas Disease Chemotherapy—A Proposal, 104 MEMORÍAS DO
INSTITUTO OSWALDO CRUZ 549, 549 (2009),
http://www.scielo.br/pdf/mioc/v104n4/02.pdf; Nitrofurans, GOLD
BIO (last visited Dec. 21, 2017),
https://www.goldbio.com/category/nitrofurans (Nitrofurans are a
class of drugs typically used as antibiotics or antimicrobials. The
defining structural component is a furan ring with a nitro group.”);
Steven Perez, Nitrofuran Analyses (FAQ), ADPEN LABORATORIES,
INC. (May 26, 2010), http://adpen.com/2010/05/nitrofurans/
(“Nitrofurans are a class of drugs that have the ability to kill microorganisms [sic].”).
135

Coura, supra note 134 at 550 (noting that the drug was sold in
Brazil “as Furacin ointment for topical use”).
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136

Johathan D. Alpern et al., Access to Benznidazole for Chagas
Disease in the United States—Cautious Optimism?, PLOS
NEGLECTED TROPICAL DISEASES 1, 3 (2017),
http://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.
0005794&type=printable; Riza Theresa Bautista-Navarro, Drug
Discovery, ENCYCLOPEDIA SYSS. BIOLOGY,
https://link.springer.com/referenceworkentry/10.1007%2F978-14419-9863-7_1340 (last visited Dec. 21, 2017), (“Empirical drug
discovery involves finding a compound that produces a desired
therapeutic effect in vitro. Initially, there is no understanding of the
candidate drug’s mechanism of action.”); Dietmar Steverding, The
Development of Drugs for Treatment of Sleeping Sickness, 3
PARASITES & VECTORS 1, 5 (2010),
https://parasitesandvectors.biomedcentral.com/track/pdf/10.1186/17
56-3305-3-15?site=parasitesandvectors.biomedcentral.com
[hereinafter Steverding, Development].
137

Alpern, supra note 136 at 3; see also Coura & Castro, supra note
130 at 5 (“Since the 1980s, [nifurtimox] had its commercialization
discontinued, first in Brazil, and then in Chile, Argentina, and
Uruguay.”). But see Steverding, History, supra note 109 at 5 (stating
that “the production of nifurtimox was suspended in 1997 due to
lack of demand”).
138

Steverding, Development, supra note 136 at 5 (explaining that
nifurtimox has shown success in treating a form of late-stage African
sleeping sickness when combined with eflornithine); Steverding,
History, supra note 109 at 5.
139

Alpern, supra note 136 at 3; Colin J. Forsyth et al., Safety Profile
of Nifurtimox for Treatment of Chagas Disease in the United States,
63 CLINICAL INFECTIOUS DISEASES 1056, 1061 (2016),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036918/pdf/ciw47
7.pdf ;
140

Alpern, supra note 136 at 3; Forsyth, supra note 139 at 1061.
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Alpern, supra note 136 at 3; Antiparasitic Treatment, CDC (last
updated Aug. 31, 2017),
https://www.cdc.gov/parasites/chagas/health_professionals/tx.html
(stating that nifurtimox is “currently available under investigational
protocols from the CDC”); Expanded Access (Compassionate Use),
U.S. FOOD & DRUG ADMIN. (last updated Oct. 3, 2017),
https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAcce
ssCompassionateUse/default.htm (explaining that expanded access
“is the use outside of a clinical trial of an investigational medical
product”).
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2. Benznidazole
1966, the pharmaceutical company Hoffman La-Roche
developed the drug benznidazole. 142 In 1971, Roche began
marketing the drug in several South American countries under the
names Rochagan, Radanil, and Ragonil. 143 In 2003, Roche
transferred its rights to benznidazole to the Brazilian government. 144
Roche and Brazil then agreed to subcontract the marketing and
production of benznidazole to “a public Brazilian agency” called the
Laboratorio Farmaceutico do Estado de Pernambuco (LAFEPE). 145
In August 2004, Roche delivered an adequate amount of the active
ingredient in benznidazole for LAFEPE to register the drug with the
Brazilian Drug Regulatory Authority (ANVISA). 146 In November
2006, ANVISA authorized LAFEPE to market benznidazole in
Brazil.147 Roche then withdrew its registration for benznidazole,
leaving LAFEPE as the sole manufacturer of benznidazole in the
world.148
142

Steverding, History, supra note 109 at 5.

143

SUMMARY REVIEW: NDA 209570 BENZNIDAZOLE, CTR. DRUG
EVALUATION & RES. 8 (2016),
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570O
rig1s000SumR.pdf [hereinafter SUMMARY REVIEW] (stating that
“Roche obtained registration of [benznidazole] in Brazil, Argentina,
Bolivia, Uruguay, Peru, and Nicaragua”).
144

SUMMARY REVIEW, supra note 143 at 8; Shortage of
Benznidazole Leaves Thousands of Chagas Patients Without
Treatment, MÉDECINS SANS FRONTIÈRES (Oct. 1, 2011),
http://www.doctorswithoutborders.org/news-stories/briefingdocument/shortage-benznidazole-leaves-thousands-chagas-patientswithout (explaining that Roche “transferred the manufacturing
technology and the license to produce to Brazil’s Pernambuco
state”); Critical Shortage of First-Line Therapy for Chagas: The
Story of Benznidalzole, MÉDECINS SANS FRONTIÈRES ACCESS
CAMPAIGN (last updated Apr. 10, 2012),
https://www.msfaccess.org/content/critical-shortage-first-linetherapy-chagas-story-benznidazole [hereinafter MSF Critical].
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145

Briefing Document, Médecins Sans Frontières, The Shortage of
Benznidazole Leaves Thousands of Chagas Patients Without
Treatment 1 (Oct. 2011),
http://www.doctorswithoutborders.org/sites/usa/files/Chagas%20brie
fing%20paper%20Final.pdf [ hereinafter MSF Briefing Document);
see SUMMARY REVIEW, supra note 143 at 8.
146

MSF Briefing Document, supra note 145 at 1 (giving the
Brazilian name of ANVISA as Agência Nacional de Vigilância
Sanitária); see SUMMARY REVIEW, supra note 143 at 8.
147

MSF Briefing Document, supra note 145 at 1; SUMMARY
REVIEW, supra note 143 at 8.
148

Alpern, supra note 136 at 2; MSF Critical, supra note 144; MSF
Briefing Document, supra note 145 at 1–2 (adding that “products
previously produced by Roche continued to be available until their
expiration date, with stocks available up to October 2010”);
SUMMARY REVIEW, supra note 143 at 8.
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Because Roche was no longer producing benznidazole,
LAFEPE need to obtain a source of the drug’s active pharmaceutical
ingredient (“API”). 149 By 2010, Roche had provided the necessary
documentation to allow a company called Nortec Química to
manufacture benznidazole’s API. 150 Although a manufacturer and an
API supplier were now in place, various administrative problems
arose that created a delay in benznidazole production. 151

149

MSF Briefing Document, supra note 145 at 2; Kathlyn Stone,
What Is an Active Pharmaceutical Ingredient (API)?, THE BALANCE
(last updated June 20, 2017), https://www.thebalance.com/apiactive-pharmaceutical-ingredient-2663020 (explaining that an API
“is the part of any drug that produces its effects” and that some drugs
“have multiple active ingredients”).
150
151

MSF Briefing Document, supra note 145 at 2.

Alpern, supra note 136 at 2 (describing the reasons for the
ensuing worldwide benznidazole shortage as “multifactorial”); MSF
Critical, supra note 144 (stating that there was “a lack of
coordination between the API supplier Nortec, LAFEPE and the
Brazilian Ministry of Health”);
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Meanwhile, the need for benznidazole was increasing.152
This increasing demand arose from various factors. 153 First, evidence
had recently demonstrated that benznidazole was effective in treating
Chagas disease patients in the chronic stage. 154 Previously,
researchers believed that the drug was only able to treat the acute
form of Chagas disease. 155 Second, recent research indicated that
patients up to age 60 could benefit from benznidazole treatment. 156
Formerly, concerns about the safety to administering benznidazoleto
adults had limited the drug’s use in older patients.157 These changes
in prescribing recommendations expanded benznidazole’s use to
treat chronic Chagas disease patients and older patients. 158
152

Alpern, supra note 136 at 2; MSF Briefing Document, supra note
145 at 2.
See MSF Briefing Document, supra note 145 at 2 (“Clear signs
showed that the demand for benznidazole was set to increase.”).
153

154

Alejandro M. Hasslocher-Moreno et al., Safety of Benznidazole
Use in the Treatment of Chronic Chagas Disease, 67 J.
ANTIMICROBIAL CHEMOTHERAPY 1261, 1261 (2012),
https://academic.oup.com/jac/article/67/5/1261/980974 (noting in
2012 that “[d]espite the controversy over the efficacy of
[benznidazole] treatment for adult patients in the chronic phase” that
“some centres advocate using [benznidazole] in order to reduce the
morbidity and mortality of the disease” and that benznidazole was
“recommended for all cases of acute, congenital, reactivated, and
chronic Chagas disease in children under 12 years of age”); MSF
Briefing Document, supra note 145 at 2.
Coura & Castro, supra note 130 at 5 (noting in 2002 that “[i]n
relation to chronic [Chagas disease] cases, results [using
benznidazole] have been poor”); MSF Briefing Document, supra
note 145 at 2 (“Initially, treatment with benznidazole was intended
only for people in the acute phase of the disease.”); Steverding,
History, supra note 109 at 5 (stating that originally, benznidazole
was “primarily used for treatment of acute cases of Chagas disease
because [it]was considered less effective in the chronic phase”).
155
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156

MSF Briefing Document, supra note 145 at 2. Compare MariaJesús Pinazo et al., Tolerance of Benznidazole in Treatment of
Chagas’ Disease in Adults, ANTIMICROBIAL AGENTS &
CHEMOTHERAPY 4896, 4896 (2010),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976114/pdf/053710.pdf (finding in 2010 that “ the unwanted side effects [of
benznidazole] are more frequent and severe in adults than in
children”), with Hasslocher-Moreno, supra note 154 at 1265
(finding in 2012 that “[t]reatment with benznidazole was considered
safe” for Chagas disease patients up to 65 years old).
157

MSF Briefing Document, supra note 145 at 2; Pinazo, supra note
156 at 4896 (noting in 2010 that “[i]n adults, benznidazole has a
high rate of adverse effects”).
158

Oliver Yun et al., Feasibility, Drug Safety, and Effectiveness in
Etiological Treatment Programs for Chagas Disease in Honduras,
Guatemala, and Bolivia; 10-Year Experience of Médecins Sans
Frontières, 3 PLOS NEGLECTED TROPICAL DISEASES 1, 7–8 (2009),
https://www.ncbi.
m.nih.gov/pmc/articles/PMC2700957/pdf/pntd.0000488.pdf (“Over
the past decade, treatment for Chagas disease has expanded from
children <12 years old, to < 15, then to <18, and finally adults.”);
MSF Briefing Document, supra note 145 at 2; see R. Viotti et al.,
Towards a Paradigm Shift in the Treatment of Chronic Chagas
Disease, 58 ANTIMICROBIAL AGENTS & CHEMOTHERAPY 635, 635
(2014), http://aac.asm.org/content/58/2/635.full.pdf+html (reviewing
“the paradigm shift” and “argu[ing] in favor of antiparasitic
treatment for all chronic [Chagas disease] patients”).
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Concurrent with the expansion of benznidazole’s
recommended use, various agencies “launched campaigns to raise
awareness of Chagas disease.”159 Médecins Sans Frontières
(MSF),160 the Drugs for Neglected Disease Initiative (DNDi), 161 the
World Health Organization (WHO), and the Pan American Health
Organization (PAHO) set forth guidelines or passed resolutions
concerning Chagas disease awareness, diagnosis, and “demand
forecasting” for benznidazole. 162 The combination of expanding
prescribing recommendations and increasing international concern
about Chagas disease led to increased demands on the world’s single
supplier of benznidazole. 163 In 2011, when LAPEFE was unable to
fill orders for benznidazole, a “global shortage ensued.”164

159

MSF Briefing Document, supra note 145 at 2.

160

About MSF, MÉDECINS SANS FRONTIÈRES (last visited Dec. 22,
2017), http://www.msf.org/en/about-msf.
161

Neglected Patients, DRUGS FOR NEGLECTED DISEASES INST. (last
visited Dec. 22, 2017), https://www.dndi.org/.
162

Chagas R&D Accelerator Initiative, World Health Organization ¶
13 (2009),
http://www.who.int/phi/implementation/chagas_R_D_accelerator_in
itiative.pdf (describing “demand forecasting” as estimating “Chagas
treatment needs of endemic countries”); MSF Briefing Document,
supra note 145 at 2; MSF Critical, supra note 144 (stating that the
“demand forecasting tool has been created to estimate demand for
benznidazole”); see Neglected Infectious Diseases and Other
Poverty-Related Diseases in the Americas, PAHO (last visited Dec.
22, 2017), http://www.paho.org/pahobranding/wpcontent/uploads/2013/08/NCD_Opt1_v1.pdf (providing public
information about NTDs—including Chagas disease—based on a
resolution from the 2009 Directing Council of PAHO).
163

MSF Briefing Document, supra note 145 at 2.
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Alpern, supra note 136 at 2 (“In 2011, a [benznidazole] shortage
occurred in the face of increased demand due to improved
recognition and screening efforts worldwide.”); MSF Briefing
Document, supra note 145 at 2; MSF Critical, supra note 144; see
Miriam Navarro et al., Short Report; Benznidazole Shortage Makes
Chagas Disease a Neglected Tropical Disease in Developed
Countries; Data from Spain, 87 AM. J. TROPICAL MED. & HYGIENE
489, 489 (2012),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435352/pdf/tropm
ed-87-489.pdf (“The current shortage of benznidazole makes
Chagas disease a neglected tropical disease also in developed
countries.”).
164
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The benznidazole shortage affected several countries,
including developed countries such as Spain. 165 Many traditionally
Chagas-endemic countries suffered significant deficits of
benznidazole during this time. 166 Additionally, global migration
from Chagas-endemic areas brought new cases of Chagas disease to
regions such as Europe and the United States. 167 These areas
suddenly needed a drug no one seemed to have. 168

165

Alpern, supra note 136 at 2; Navarro, supra note 164 at 489
(stating that [i]n Spain alone, at least 5,003,460 benzinadazole
tablets [were] needed” and that “more than 23,000 [would] not
receive the treatment they need[ed]”).
166

Press Release, Médecins Sans Frontières, Treatment Ends for
Chagas Patients (Oct. 5, 2011), https://www.msfaccess.org/aboutus/media-room/press-releases/treatment-ends-chagas-patients
[hereinafter Press Release] (stating that Chagas disease in “endemic
in several Latin American countries” and that the shortage of
benznidazole was creating situations that were “not acceptable” in
Brazil, Bolivia, and Paraguay); MSF Briefing Document, supra note
145 at 4 (stating that in 2011, LAFEPE “informed MSF” that
LAFEPE would be unable to fill MSF’s orders for benznidazole in
Boliva, Paraguay, and Columbia).
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Some relief arrived in 2012, when an Argentine company,
Maprimed, became a benznidazole API supplier to an Argentine
pharmaceutical company, ELEA. 169 ELEA distributed its
benznidazole product, Abrax, to Latin American countries, including
Bolivia, Paraguay, Chile, and Argentina.170 Currently, LAPEFE and
ELEA are the only sources of benznidazole in the world.

167

Mauizio Bonati & Valeria M. Confalonieri, Global Rights for
Global Diseases: The Shortage of Benznidazole Case, 22 EUR. J.
PUB. HEALTH (2012),
https://academic.oup.com/eurpub/article/doi/10.1093/eurpub/el_316/
2547684 (noting that “as a result of migration and travel from [Latin
America], [Chagas disease] is now also present in non endemic [sic]
countries, including those in many European regions (in Belgium,
France, Italy, Spain, Switzerland, the United Kingdom)”); Press
Release, supra note 166 (stating that “Chagas disease . . . is a highly
important but little-addressed public health issue, not only in Latin
America but also increasingly in non-endemic, developed countries,
due to globalization and population flows”); see Navarro, supra note
164 at 489–90 (stating that Bolivia has the “highest [Chagas] disease
burden in the world” and that in 2011, 206,635 registered migrants
from Bolivia lived in Spain—25,080 of whom were adults infected
with T. cruzi).
See Bonati & Confalonieri, supra note 167 (“Such an illogical
situation, in which lifesaving treatment for millions of people
depends wholly on a single pharmaceutical company . . . should
make everyone think.”).
168

169

SUMMARY REVIEW, supra note 143 at 8; Alpern, supra note 136
at 2–3.
SUMMARY REVIEW, supra note 143 at 8 (noting that Abrax “is
also available in Spain”); Alpern, supra note 136 at 3.
170
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III.

The Road to FDA Approval
On August 20, 2015, the FDA set forth an order describing
the criteria by which a disease may be added to the list of NTD
eligible for a PRV.171 The Food, Drug, and Cosmetic (FD&C) Act
originally contained a list of sixteen tropical diseases for which the
FDA could grant a PRV.172 Section 524 of the FD&C Act provided
the authority under which the FDA could designate another tropical
disease as PRV-eligible.173 The FDA’s order also “opened a docket
to receive recommendations from the public for future additions to
the list.”174 Additionally, the FDA order added Chagas disease and
neurocysticercosis to the list of NTDs in the FD&C Act. 175

171

21 U.S.C. § 360n (2008), https://www.kidsvcancer.org/wpcontent/uploads/2008/05/FDCActChapter-V_DrugsandDevicesPriority-Review-to-Encourage-Treatments-for-TropicalDiseases.pdf; Designating Additions to the Current List of Tropical
Diseases in the Federal Food, Drug, and Cosmetic Act, 21 C.F.R. §
317 (2015),
https://www.federalregister.gov/documents/2015/08/20/201520554/designating-additions-to-the-current-list-of-tropical-diseasesin-the-federal-food-drug-and-cosmetic.
172

21 U.S.C. § 360n (2008); Ridley, Priority Review Vouchers,
supra note 21; cf. 21 U.S.C. § 360n (2017) (including Filovirus
diseases and Zika virus diseases on the list of NTDs, both of which
legislation added in 2014).
21 U.S.C § 360n(a)(3)(S) (“Any other infectious disease for
which there is no significant market in developed nations and that
disproportionately affects poor and marginalized populations,
designated by order of the Secretary.”); 21 C.F.R. § 317; TDPRV
GUIDANCE, supra note 67 at 4.
173

174
175

21 C.F.R. § 317; TDPRV GUIDANCE, supra note 67 at 4.

21 C.F.R. § 317; TDPRV GUIDANCE, supra note 67 at 4; Ridley,
Priority Review Vouchers, supra note 21.
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A. The Race for the Benznidazole PRV
Once the FDA added Chagas disease to list its list of NTD,
interest in acquiring FDA approval for benznidazole soared. 176 In
November 2015, Martin Shkreli, former hedge fund manager and
founder of Turing Pharmaceuticals, became CEO of the California
biotechnology company KaloBios. 177 On December 3, 2015,
KaloBios announced its purchase of the rights to benznidazole from
Savant Neglected Diseases. 178 In a press release, KaloBios stated its
intent to “file for Orphan Drug Designation and Fast Track
Designation for benznidazole in Chagas Disease.” 179 Additionally,
KaloBios expected to receive a PRV if the FDA approved
benzndazole.180

176 JEREMY

BAROFSKY & JAKE SCHNEIDER , PROMOTING PRIVATE
SECTOR INVOLVEMENT IN NEGLECTED TROPICAL DISEASE RESEARCH
AND DEVELOPMENT 11 (2017), https://www.brookings.edu/wpcontent/uploads/2017/12/br_health4_optimized_final.pdf
(“Following the addition of Chagas disease to the list of PRV
eligible conditions, market activities for Chagas disease increased
substantially.”); Courtney Columbus, Drug for ‘Neglected’ Chagas
Disease Gains FDA Approval Amid Price Worries, NPR (Sept. 10,
2017), https://www.npr.org/sections/healthshots/2017/09/10/547351794/drug-for-neglected-chagas-diseasegains-fda-approval-amid-price-worries (explaining that benznidazole
was “the best of the two available options for treating Chagas”
because benznidazole is “more toxic” than nifurtimox); id. (referring
to a PRV as a “potential gold mine” and a “golden ticket” for
pharmaceutical companies); Daisy Hernández, A New Strategy to
Undermine Big Pharma’s Price Gouging Actually Worked, SLATE
(Sept. 7, 2017),
http://www.slate.com/articles/health_and_science/medical_examiner
/2017/09/inside_the_battle_to_approve_a_chagas_treatment.html
(stating that “[w]ith its inclusion on that federal list in 2015, Chagas
became a cash cow in the pharma world”).
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Damian Garde, Shkreli’s KaloBio Buys an Old Drug with Eyes on
a Lucrative FDAVoucher, FIERCE BIOTECH (Dec. 4, 2015),
https://www.fiercebiotech.com/financials/shkreli-s-kalobios-buysan-old-drug-eyes-on-a-lucrative-fda-voucher (describing KaloBios
as “a once-doomed company brought back from the brink by biotech
entrepreneur Martin Shkreli”); David Goldman, Who is Martin
Shkreli? A Timeline, CNN MONEY (Dec. 18, 2015),
http://money.cnn.com/2015/12/18/news/companies/martinshkreli/index.html (“Shkreli formed Turing Pharmaceuticals in
February 2015, which bought the rights to Daraprim, a
toxoplasmosis treatment used by AIDS patients.”); see id. (“Turing
caught fire in September 2015 for hiking the price of Daraprim. A
single pill, which had cost $13, was raised 5,000% to $750.”);
Andrew Pollack, Drug Goes From $13.50 a Tablet to $750,
Overnight, N.Y. TIMES (Sept. 20, 2015),
https://www.nytimes.com/2015/09/21/business/a-huge-overnightincrease-in-a-drugs-price-raises-protests.html.
177

178

Press Release, KaloBios, KaloBios Announces Agreement to
Acquire Benznidazole Program for the Treatment of Chagas Disease
(Dec. 3, 2015), https://ir.humanigen.com/pressreleases/detail/71/kalobios-announces-agreement-to-acquirebenznidazole [hereinafter KaloBio Press Release] (stating that
KaloBios was to pay Savant “an upfront payment of $ 2 million, plus
regulatory milestones and a royalty based on sales”).
Id.; Garde, supra note 177 (“KaloBios plans to file to the FDA’s
fast-track designation in hopes of scoring a quick approval for
benznidazole without running any clinical trials of its own.”).
179

180

KaloBios Press Release, supra note 178; Garde, supra note 177
(“And, because [Chagas disease] is on the FDA’s list of neglected
tropical ailments, winning approval would grant KaloBios a
tradeable coupon that shortens drug reviews by four months.”).
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After forming the agreement with Savant, Shkreli told
KaloBios investors that the price of benznidazole would be similar to
the price of hepatitis C drugs. 181 KaloBios’s price for benznidazole
would have cost Chagas disease patients between $60,000 and
$100,000 per treatment.182 On December 17, 2015, the FBI arrested
KaloBios CEO Martin Shkreli on securities fraud charges. 183 That
same day, KaloBios fired Shkreli. 184 The value of KaloBios’s stock
plunged after news of Shkreli’s arrest became public. 185 However,
KaloBios continued to pursue FDA approval of benznidazole
following Shkreli’s dismissal. 186

181

Laura Bult, Martin Skhreli Plans to Raise Price of Drug for
Parasitic Infection Chagas Disease, N.Y. DAILY NEWS (stating that
during a public conference call with investors “Shkreli gleefully
announced the purchase of the Chagas treatment and said that he
would price the drug, benzinidazole, similarly to hepatitis C drugs”);
Andrew Pollack, Martin Shkreli’s Latest Plan to Sharply Raise Drug
Price Prompts Outcry, N.Y. TIMES (Dec. 11, 2015),
https://www.nytimes.com/2015/12/12/business/martin-shkrelislatest-plan-to-sharply-raise-drug-price-promptsoutcry.html?mcubz=3 [hereinafter Pollack Outcry]; see Forward
Looking Statements, KaloBios Pharmaceuticals (Dec. 2015),
https://www.sec.gov/Archives/edgar/data/1293310/00011046591508
2792/a15-24519_1ex99d1.htm (stating under the heading
“Commercial Opportunities” that benznidazole “[p]ricing expected
to be similar to Hepatitis C antivirals”).
182
183

Pollack Outcry, supra note 181.

Chris Isidore & Aaron Smith, Reviled Drug CEO Martin Shkreli
Arrested, CNN MONEY (Dec. 18, 2015),
http://money.cnn.com/2015/12/17/news/companies/martin-shkreliarrest-reports/index.html (noting that the federal case against Shkreli
“center[ed] on his time as CEO of Retrophin, . . . another biotech
company that ousted him last year”).
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184

KaloBios Fires Shkreli as CEO, REUTERS (Dec. 21, 2015),
https://www.reuters.com/article/us-usa-crime-shkreli/kalobios-firesshkreli-as-ceo-idUSKBN0U41R720151221.
185

Laura Lorenzetti, KaloBios Just Fired Martin Shkreli as CEO,
FORTUNE (Dec. 21, 2015), http://fortune.com/2015/12/21/martinshkreli-kalobios/.
186

See BRIEF—KaloBios to Have FDA Meeting for Using
Benznidazole for Treating Chagas Disease, REUTERS (Dec. 5, 2016),
https://www.reuters.com/article/idUSFWN1E00AT [hereinafter
BRIEF]; Beth Mole, In Comeback Bid, Shkreli’s Old Company Gets
OK to Buy Life-Saving Drug, ARS TECHNICA (Feb. 27, 2016),
https://arstechnica.com/science/2016/02/in-comeback-bid-shkrelisold-company-gets-ok-to-buy-life-saving-drug/ (stating that a
Delaware bankruptcy court authorized KaloBios to continue its
purchase of benznidazole rights from Savant).
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The U.S. and international medical communites reacted to
KaloBios’s possible price-jacking of benznidazole with considerable
concern and apprehension. 187 The price of benznidazole in many
Chagas disease-endemic countries was $50 to $100 per treatment. 188
Further, the CDC had been dispensing benznidazole at no cost to
patients participating in investigational protocols. 189 To allow
KaloBios to obtain FDA approval of benznidazole and then
drastically raise its price was unacceptable to public health care
advocates.190 Consequently, two non-profit groups and a
pharmaceutical company formed a partnership and “set out . . . to
register the drug where its [sic] needed, including the U.S.”191

187

Press Release, Drugs for Neglected Diseases initiative, DNDi
statement on KaloBios’ [sic] Intention to Raise Price of Chagas Drug
and File for FDA Priority Review (Dec. 14, 2015),
https://www.dndi.org/2015/media-centre/press-releases/dndistatement-on-kalobios-intention-to-raise-price-of-chagas-drug-andfile-for-fda-priority-review-2/ [hereinafter Press Release DNDi]
(quoting Dr. Bernard Pécoul, Executive Director of Drugs for
Neglected Diseases initiative (DNDi) as saying that “[a]t this point,
we see the move by KaloBios as a direct threat to affordable
benznidazole both in the U.S. and in Latin America”); Mole, supra
note 186 (“When KaloBios and Shkreli first revealed the plan late
last year, it sparked public outcry from public health experts and
infectious disease doctors who feared that the new cost would make
it difficult for the millions of patients in Central and South America
to get the drug.”); Pollack Outcry, supra note 181 (“ ‘It’s caused a
lot of angst in the Chagas community,’ said Dr. Sheba Meymandi . .
. .‘Everyone’s in an uproar.’ ”).
188

Press Release DNDi, supra note 187; Pollack Outcry, supra note
181.
189

Alpern, supra note 136 at 3; Pollack Outcry, supra note 181. But
see Hernández, supra note 176 (noting that “between 2007 and 2013
the [CDC] only released 422 doses of both benznidazole and
[nifutimox]”).

CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW

290

See Press Release DNDi, supra note 187 (“We could face a
nightmare situation for Chagas patients and healthcare providers in
the US: the drug will finally be registered, but it could be even less
accessible than it is today.”); Hernández, supra note 176 (“What
Shkrelu didn’t count on were the people—physicians and
advocates—who would be outraged over his tatics.”); DNDi, Mundo
Sano, and Chemo Team Up to Register Benznidazole in US and
Latin America, INSUD PHARMA (June 9, 2016),
http://www.insudpharma.com/dndi-mundo-sano-and-chemo-teamregister-benznidazole-us-and-latin-america [hereinafter DNDi,
Mundo Sano, and Chemo] (quoting DNDi’s Executive Director as
saying: “Our ambition is to put an end to a scandalous and
unjustifiable situation where almost none of the people living with
Chagas has access to existing treatments”).
190

John Carroll, A Non-Profit Group’s Chagas Drug Beat Out
Martin Shkreli’s Old Rival to FDA OK, Valuable PRV, ENDPOINT
NEWS (Aug. 30, 2017), https://endpts.com/fda-oks-nonprofit-groupsold-chagas-drug-handing-out-prv-and-clearing-way-to-cheap-price/;
DNDi, Mundo Sano, and Chemo, supra note 190 (describing DNDi
as a “non-profit drug development organisation [sic],” Mundo Sano
as a “non-profit foundation,” and Chemo Group as a
“pharmaceutical company” that is a “corporate responsibility
partner” with Mundo Sano, and stating that the trio “are entering into
a formal collaboration to boost affordable access to benznidazole”).
191
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In June 2106, Drugs for Neglected Diseases initiative
(DNDi), Mundo Sano, and Chemo Group entered into formal
agreements to provide benznidazole to the 300,000 Chagas disease
patients in the United States. 192 The team also hoped to increase the
worldwide availability of benznidazole while maintaining the drug’s
attainable cost. 193 Chemo Group sought to gain FDA approval for
benznidazole in 2013— before the FDA added Chagas disease
treatments to the list of PRV eligible drugs. 194 In the agreement with
Mundo Sano, DNDi committed to providing research data and
support.195 Additionally, Chemo Group would give Mundo Sano half
of “any PRV-related financing” if Chemo Group secured a PRV.196
The agreement then stipulated that “DNDi and Mundo Sano would
manage jointly those funds” to support non-profit activities
benefitting Chagas disease patients. 197 Moreover, Chemo Group
agreed to provide benznidazole “on an affordable basis.” 198

192

DNDi, Mundo Sano, and Chemo, supra note 190; (calling the
group’s effort a “bid to overturn a situation where less than 1% of
people with Chagas disease have access to treatment”); Eric
Sagonowsky, FDA Blesses Nonprofit-Backed Chagas Drug,
Thwarting Ex-Shkrei Biotech’s Bid for Rival Launch, FIERCE
PHARMA (Aug. 20, 2017) (“Chemo Group is a Spanish multinational
pharma that sells generics and branded drugs, and it runs an
Argentina-based nonprofit foundation, Mundo Sano.”); see Press
Release, FDA Approves, supra note 4 (stating that “recent estimates
are that there may be approximately 300,000 persons in the United
States with Chagas disease”).
193

DNDi, Mundo Sano, and Chemo, supra note 190 (stating that
Chemo Group was “commit[ted] to ensuring [benznidazole] is
available to the public sector in Chagas-endemic areas on an
affordable basis”).
194

BAROFSKY & SCHNEIDER, supra note 176 at 11; Hernández, supra
note 176 (“The pharmaceutical company Chemo Group had been
trying to register the drug with the FDA before the disease was even
tied to the voucher.”).
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195

Hernández, supra note 176; see BAROFSKY & SCHNEIDER, supra
note 176 at 11(“DNDi provided technical expertise, including data
from two DNDi-led clinical trials of benznidazole that were used in
the FDA application.”).
196

DNDi, Mundo Sano, and Chemo, supra note 190.

Id. (stating that the funds would “be dedicated to actions that
benefit patients and encourage access, by supporting not-for-profit
programs to scale up diagnosis and treatment for Chagas disease”);
Sagonowsky, supra note 192 (stating that fifty percent of the
revenue from a PRV sale would fund a ‘far-reaching’ access
program to ensure supply in the U.S. and other countries); see also
BAROFSKY & SCHNEIDER, supra note 176 at 11 (noting that in
addition to providing research data for benznidazole, DNDi is
searching for new pharmaceutical treatments for Chagas disease);
U.S. FDA Approves Chemo Group’s Benznidazole to Treat Children
with Chagas Disease, DNDi (Aug. 31, 2017),
https://www.dndi.org/2Press Release, FDA, FDA Approves First
Treatment for Chagas Disease017/media-centre/press-releases/fdaapproves-benznidazole-chagas-children/ (“DNDi is also involved in
early-stage research for entirely new drugs for Chagas Disease.”).
197

198

DNDi, Mundo Sano, and Chemo, supra note 190 (explaining that
an “affordable basis” would involve “a price that covers
manufacturing and distribution costs plus a reasonable margin”); cf.
Hernández, supra note 176 (stating that in its agreement with DNDi
Chemo Group would “provide benznidazole on a “no profit no loss”
basis”).
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Despite its early setback with Shkreli, KaloBios continued
its pursuit of FDA approval of benznidazole throughout 2016 and
into the first half of 2017. 199 In December 2016, KaloBios completed
a face-to-face meeting with the FDA and in January 2017, the FDA
gave KaloBios positive guidance on benznidazole. 200 In May 2017,
the FDA accepted KaloBios’s Investigational New Drug application
for benznidazole. 201 In July 2017, the FDA granted KaloBios’s
sponsorship request to designate benznidazole as an orphan drug. 202

199

See BRIEF, supra note 186 (stating on December 5, 2016, that
KaloBios “expect[ed] to have an FDA meeting to confirm regulatory
pathway for benznidazole in treatment of Chagas disease”); Mole,
supra note 186 (stating in February 2016 that KaloBios “may now
be poised for a comeback” and that KaloBios had “renewed [its]
plan to buy the worldwide regulatory rights to benznidazole from
Savant”).
200

JGR CAPITAL PARTNERS, KALOBIOS PHARMACEUTICALS, INC., 1
(2017), https://www.jgrcap.com/wp-content/uploads/2017/05/KBIOMay-2-2017-RE.pdf (stating that the “FDA accepted [KaloBios’s]
intention to use existing safety and efficacy data from previous
studies”); Press Release, KaloBios Pharmaceuticals, Inc., KaloBios
Announces Positive Guidance from FDA for Benznidazole (Jan.5,
2017), https://ir.humanigen.com/press-releases/detail/88/kalobiosannounces-positive-guidance-from-fda-for (“This guidance makes it
clear that we are on the right track with our development of
benznidazole, and we expect we will progress expeditiously toward a
submission . . . .”); KaloBios Pharma (KBIO) Completes Face-toFace Meeting with FDA for Benznidazole, STREET INSIDER (Dec. 12,
2016),
https://www.streetinsider.com/Corporate+News/KaloBios+Pharma+
%28KBIO%29+Completes+Face-toFace+Meeting+with+FDA+for+Benznidazole/12332118.html; see
Ciara Linnane, KaloBios Stock Jumps on News of Positive Guidance
from Rare Disease Drug, MARKET WATCH (Jan. 5, 2017),
https://www.marketwatch.com/story/kalobios-stock-jumps-on-newsof-positive-guidance-from-fda-on-rare-disease-drug-2017-01-05
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201

Press Release, KaloBios Pharmacueticals, Inc., Benznidazole
IND for Chagas Disease Receives Clearance by FDA (June 27,
2017), https://ir.humanigen.com/press-releases/detail/107 .
202

KaloBios Recieves Orphan Drug Designation for Benznidazole in
the treatment of Chagas Disease, NASDAQ GLOBENEWSWIRE (July
11, 2017), https://globenewswire.com/newsrelease/2017/07/11/1042699/0/en/KaloBios-Receives-Orphan-DrugDesignation-for-Benznidazole-in-the-Treatment-of-ChagasDisease.html; Search Orphan Drug Designations and Approvals
(Benznidazole), U.S. FOOD & DRUG ADMIN. (last visited Dec. 25,
2017),
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cf
m (hereinafter Search Orphan Drug] (listing a “designated” but not
approved status for KaloBios’s sponsorship of benznidazole).
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However, the FDA had granted Chemo Group orphan drug
status for benzinidazole back in 2014. 203 Although Kalo Bios
“outlined an approach to pricing benznidaole fairly,” 204 Chemo
Group persisted in its efforts to gain FDA approval. 205 Chemo Group
submitted an NDA with the FDA on December 29, 2016. 206

203

Search Orphan Drug, supra note 202 (listing an April 14, 2014
“designated/approved” date for Chemo Group’s sponsorship of
benznidazole); see Jeff Antos, Common Misconceptions About the
Orphan Drug Designation, PHARM. COM. (Mar. 3, 2014),
http://pharmaceuticalcommerce.com/opinion/commonmisconceptions-about-the-orphan-drug-designation/ (explaining that
“more than one sponsor can receive an orphan designation for the
same drug/indication”).
U.S. SEC & EXCH. COMMI’N, FORM 10-K, KALOBIOS
PHARMACEUTICALS 4 (2017), https://ir.humanigen.com/all-secfilings/content/0001214659-17-001799/0001214659-17-001799.pdf
(“Upon regulatory approval of any of our products, we intend to
apply our Reasonable Pricing Model, which focuses on affordability
for patients and payers, transparency for all stakeholders, and
delivery of a reasonable return in recognition of the risks we are
taking in our development efforts.”).
204

See Alpern, supra note 136 (noting that Chemo Group’s efforts
afforded patients and the medical community “reasons for cautious
optimism for affordable and dependable access to benznidazole” and
that “[w]e are left watching and waiting to see who obtains FDA
approval” for benznidazole).
205

206

SUMMARY REVIEW, supra note 143 at 9.
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B. The FDA Approval of Benznidazole for Chagas Disease
Finally, on August 29, 2017, the FDA approved Chemo
Group’s NDA for benznidazole for the treatment of Chagas disease
in children ages 2 to 12. 207 Additionally, the FDA granted Chemo
Group a PRV.208

207

SUMMARY REVIEW, supra note 143 at 1; Press Release, FDA
Approves, supra note 4 (“The U.S. Food and Drug Administration
today granted accelerated approval to benznidazole for use in
children ages 2 to 12 years with Chagas disease.”); see Hernández,
supra note 176 (noting that “doctors will still be able to prescribe
[benznidazole] off-label for adults”); Sagonowsky, supra note 192
(adding that Chemo Group, Mundo Sano, and DNDi “picked up
seven years of orphan drug exclusivity for benznidazole; see also
Jaime Altcheh et al., Population Pharmacokinetic Study of
Benznidazole in Pediatric Chagas Disease Suggests Efficacy Despite
Lower Plasma Concentrations Than in Adults, 8 PLOS NEGLECTED
TROPICAL DISEASES 2 (2014),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031103/pdf/pntd.0
002907.pdf (stating in the author summary that although “the
elimination of [benznidazole] is significantly faster in children than
in adults, leading to lower plasma concentrations . . . . unlike adults,
all children in the study responded well and had few adverse
reactions to the drug”); Mario J. Olivera et al., Risk Factors for
Treatment Interruption and Severe Adverse Effects to Benznidazole
in Adult Patients with Chagas Disease, PLOS ONE 2 (2017),
http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.
0185033&type=printable (stating that [i]n some adult [Chagas
disease] populations the incidence of [adverse drug effects] has
reached up to 100%”).
Press Release, FDA Approves, supra note 4 (stating that “[w]ith
this approval, benznidazole’s manufacturer, Chemo Research, S.L.,
is awarded a Tropical Disease Priority Review Voucher in
accordance with a provision included in the Food and Drug
Administration Amendment Act of 2007”).
208
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Chemo Group’s pharmaceutical division, Exeltis, will
distribute benznidazole in the United States. 209 Although the FDA
approval was a victory for the Chemo/Mundo Sano/DNDi group, the
trio still has challenges to face. 210 For example, Chemo Group’s
ability to affordably provide benznidazole to Chagas patients may
not be a simple task. 211 Because the CDC has treated many U.S.
Chagas patients for free, some concern exists over these patients’
ability to afford and access the drug. 212 Additional variables may
arise, such as providing access to benznidazole through local
pharmacies and “reach[ing] patients who might not even know they
are infected.”213 However, the FDA approval of benznidazole
represents a crucial step in Chagas disease treatment worldwide. 214

209

Exeltis US Will Distribute Benznidazole for the Treatment of
Chagas Disease in Patients 2–12 Years Old, EXELTIS (Aug. 31,
2017), http://www.exeltis.com/exeltis-us-will-distributebenznidazole-treatment-chagas-disease-patients-aged-2-12-years-old
(“Exeltis will use its operational and technical platform to support
the availability of benznidazole in the United States in support of
Mundo Sano—to help minimize cost and ensure compliance with
FDA regulations”).
Press Release DNDi, supra note 187 (stating that “Chemo Group
will continue working . . . to overcome barriers to treatment of
Chagas disease” and that “Mundo Sano and DNDi will pursue
efforts to boost access and increase patient awareness”).
210

211

Columbus, supra note 176 (stating that a concern exists that
“many Chagas patients will need financial help” and that for some
patients “almost any price would be too high”).
Id. (noting that “having the CDC supply of the drug has been
crucial”).
212

213

Hernández, supra note 176.
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Press Release DNDi, supra note 187 (“ ‘I am thrilled that we are
taking a giant step forward in our journey to overcome to many
barriers to Chagas treatment,’ said Dr. Silvia Gold, President of
Mundo Sano.”); Drug to Treat Chagas Disease to Become Available
in the U.S., MÉDECINS SANS FRONTIÈRES (Aug. 31, 2017),
http://www.doctorswithoutborders.org/article/drug-treat-chagasdisease-become-available-us [hereinafter MSF Drug to Treat]
(stating that the “registration and availability of this medicine in the
United States is a positive step for children with Chagas in the U.S.”
and that “[w]ithout treatment, many Chagas patients are at risk of
dying from complications, and few patients in the U.S. currently
diagnosed and treated for this disease”).
214
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IV.

CONCLUSION
The PRV program played a critical role in helping to bring
benznidazole to Chagas disease patients in the United States. 215
Although benznidazole had been available to treat Chagas disease
since 1971, 216 the U.S. pharmaceutical industry ignored the drug
until the FDA provided the PRV incentive for a Chagas disease
treatment.217 The time from the FDA’s addition of Chagas disease to
the list of NTDs to the FDA’s approval of benznidazole for Chagas
disease was two years and nine days. 218 The PRV incentive brought
two pharmaceutical companies into fierce competition with one
another to obtain FDA approval for a drug that had existed for more
than forty years.219 Thus, in the FDA approval of benznidazole, the
PRV program appears to have succeeded in its original goal to
“encourage the development of new drug and biological products for
the prevention and treatment of certain tropical diseases affecting
millions of people throughout the world.”220

215

Supra text accompanying note 176; see Press Release, FDA
Approves, supra note 4 (“The FDA granted benznidazole priority
review . . . because Chagas disease is a rare disease and until now,
there were no approved drugs for Chagas disease in the United
States.”).
216

Supra text accompanying note 143.

MSF Drug to Treat, supra note 214 (“The FDA also announced
that Chemo will receive a lucrative Priority Review Voucher (PRV)
for registering benznidazole even though the drug has been used to
treat Chagas disease in adults in Latin America for more than 40
years.”).
217

218

See 21 C.F.R. § 317 (stating that on August 20, 2017, the FDA
added Chagas disease to the list of NTDs—the treatment for which
the FDA would award a PRV upon FDA approval); Press Release,
FDA Approves, supra note 4 (announcing the FDA approval of
benznidazole and the FDA’s PRV award to Chemo Group on August
29, 2017).
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MSF Drug to Treat, supra note 214 (stating that Chemo Group,
Mundo Sano, and DNDi “beat” KaloBios in the bid for FDA
approval for benznidazole).
220

TDPRV GUIDANCE, supra note 68 at 1.
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Yet, the original authors of the PRV concept had a more
expansive goal of “achieving better population health.” 221 Ridley et
al. included two criteria in their paper that Congress did not include
in the PRV legislation. 222 First, the PRV concept’s authors proposed
that the FDA award PRVs for therapies that are “clinically superior
to existing treatments.”223 Second, the winner of the PRV should
“forgo patent rights” for the drug. 224 The authors included these
criteria to further the goal of “help[ing] people suffering from
neglected diseases who are in need of new medicines that are
affordable and available regardless of where they live.” 225 Including
these requirements in future legislation would increase the PRV
program’s ability to truly “develop drugs for developing nations.” 226

221

See Ridley, Developing Drugs, supra note 20 at 313 (proposing a
PRV incentive program that “could benefit consumers in both
developing and developed countries” by “speed[ing] access to highly
valued treatments”).
Compare Ridley, Developing Drugs, supra note 20 at 315 (“To
receive a voucher, a therapy must . . . (3) be clinically superior to
existing treatments, (4) forgo patent rights . . . . ”) with 21 U.S.C. §
360n (lacking provisions contained in the original proposal paper by
Ridley et al.).
222

223

Ridley, Developing Drugs, supra note 20 at 315.

224

Id.

225

David Ridley & Jeffery Moe, An FDA Drug Voucher Program
Needs a Reboot, THE HILL (June 30, 2017),
http://thehill.com/blogs/pundits-blog/healthcare/339913-fdasneglected-disease-incentives-need-teeth-to-ensure-patient
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Id. (explaining that “limit[ing] vouchers to rewarding only new
drugs and vaccines . . .will reduce the supply of vouchers and
increase their price” and that requiring “voucher winners [to] forgo
their patent rights” would hold drug companies “publically
accountable to make their treatments available to where it is most
needed”).
226
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While the benznidazole approval appears to validate the PRV
program, Chagas patients may have narrowly dodged a bullet. 227
Although legislation enacted in August 2017 that expanded the PRV
program requirements, additional concerns remain. 228 U.S.
lawmakers should continue refining the PRV program to meet the
needs of neglected disease patients everywhere. 229
Hernández, supra note 176 (stating that the “unique agreement”
between Chemo Group, Mundo Sano, and DNDi “fills in some gaps
that scholars who created the priority review voucher program 10
years ago have said they now want to incorporate”); see MSF Drugs
to Treat, supra note 214 (noting that while it is “good news that
Chemo has made a commitment to promote access to the drug . . . .
other companies have abused the PRV program for neglected
diseases without any benefit to the patient”); see infra note 170 and
accompanying text.
227

228

FDA Reauthorization Act of 2017, Pub. L. No. 115-52, 131 Stat.
1005, https://www.congress.gov/bill/115th-congress/housebill/2430; FDA User Fee Reauthorization Legislation Enacted by
Congress, ROPES & GRAY (Aug. 7, 2017),
https://www.ropesgray.com/newsroom/alerts/2017/08/FDA-UserFee-Reauthorization-Legislation-Enacted-by-Congress.aspx
(explaining that the FDA Reauthorization Act tropical disease PRV
provision requires “applicants to demonstrate they conducted or
sponsored at least one clinical investigation essential to the
application”); FDA Reauthorization Act Passes U.S. House and
Senate Without Fixes to Deliver Urgently Needed New Drugs,
Vaccines for Neglected Diseases, MÉDECINS SANS FRONTIÈRES
(Aug. 2, 2107), http://www.doctorswithoutborders.org/article/fdareauthorization-act-passes-us-house-and-senate-without-fixesdeliver-urgently-needed-new (“Both chambers of U.S. Congress
missed another opportunity to help people living with neglected
diseases by passing the FDA Reauthorization Act (FDAFA) of 2017
today without fixing the [FDA’s PRV] program for neglected
diseases.”); see Ridley & Moe, supra note 225 (“Unfortunately, the
fix as written to the FDA Reauthorization Act does too little to help
the millions of people at risk for these diseases.”).
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MSF Drugs to Treat, supra note 214 (“Before a company can
receive this prize, U.S. Congress should mandate that only new
medicines receive a PRV and that companies ensure access and
affordability for all patients.”); Ridley & Moe, supra note 225
(explaining that Congress should enact “[t]ighter eligibility [that]
would bolster the value of vouchers by reducing the supply”).
229
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